Literature DB >> 33249747

Interleukin 6 trans-signaling is a critical driver of lung allograft fibrosis.

David S Wheeler1, Keizo Misumi1, Natalie M Walker1, Ragini Vittal1, Michael P Combs1, Yoshiro Aoki1, Russell R Braeuer1, Vibha N Lama1.   

Abstract

Histopathologic examination of lungs afflicted by chronic lung allograft dysfunction (CLAD) consistently shows both mononuclear cell (MNC) inflammation and mesenchymal cell (MC) fibroproliferation. We hypothesize that interleukin 6 (IL-6) trans-signaling may be a critical mediator of MNC-MC crosstalk and necessary for the pathogenesis of CLAD. Bronchoalveolar lavage (BAL) fluid obtained after the diagnosis of CLAD has approximately twofold higher IL-6 and soluble IL-6 receptor (sIL-6R) levels compared to matched pre-CLAD samples. Human BAL-derived MCs do not respond to treatment with IL-6 alone but have rapid and prolonged JAK2-mediated STAT3 Tyr705 phosphorylation when exposed to the combination of IL-6 and sIL-6R. STAT3 phosphorylation within MCs upregulates numerous genes causing increased invasion and fibrotic differentiation. MNC, a key source of both IL-6 and sIL-6R, produce minimal amounts of these proteins at baseline but significantly upregulate production when cocultured with MCs. Finally, the use of an IL-6 deficient recipient in a murine orthotopic transplant model of CLAD reduces allograft fibrosis by over 50%. Taken together these results support a mechanism where infiltrating MNCs are stimulated by resident MCs to release large quantities of IL-6 and sIL-6R which then feedback onto the MCs to increase invasion and fibrotic differentiation.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  animal models: murine; basic (laboratory) research / science; bronchiolitis obliterans (BOS); cellular biology; cytokines / cytokine receptors; fibrosis; lung transplantation / pulmonology; translational research / science

Mesh:

Substances:

Year:  2021        PMID: 33249747      PMCID: PMC8809084          DOI: 10.1111/ajt.16417

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   9.369


  51 in total

Review 1.  JAK-STAT signaling: from interferons to cytokines.

Authors:  Christian Schindler; David E Levy; Thomas Decker
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

Review 2.  Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map.

Authors:  Jennifer Huynh; Ashwini Chand; Daniel Gough; Matthias Ernst
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

3.  Local origin of mesenchymal cells in a murine orthotopic lung transplantation model of bronchiolitis obliterans.

Authors:  Takeshi Mimura; Natalie Walker; Yoshiro Aoki; Casey M Manning; Benjamin J Murdock; Jeffery L Myers; Amir Lagstein; John J Osterholzer; Vibha N Lama
Journal:  Am J Pathol       Date:  2015-04-04       Impact factor: 4.307

4.  Circulating levels of soluble interleukin-6 receptor in patients with bronchial asthma.

Authors:  A Yokoyama; N Kohno; K Sakai; K Kondo; Y Hirasawa; K Hiwada
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

5.  Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation.

Authors:  J Scholma; D J Slebos; H M Boezen; J W van den Berg; W van der Bij; W J de Boer; G H Koëter; W Timens; H F Kauffman; D S Postma
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

6.  Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.

Authors:  Jaehyup Kim; Peiman Hematti
Journal:  Exp Hematol       Date:  2009-09-20       Impact factor: 3.084

7.  Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.

Authors:  D Heng; L D Sharples; K McNeil; S Stewart; T Wreghitt; J Wallwork
Journal:  J Heart Lung Transplant       Date:  1998-12       Impact factor: 10.247

8.  Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets.

Authors:  K M Fries; M E Felch; R P Phipps
Journal:  Am J Respir Cell Mol Biol       Date:  1994-11       Impact factor: 6.914

9.  Benefits of posttransplantation monitoring of interleukin 6 in lung transplantation.

Authors:  Y Yoshida; Y Iwaki; S Pham; J H Dauber; S A Yousem; A Zeevi; S Morita; B P Griffith
Journal:  Ann Thorac Surg       Date:  1993-01       Impact factor: 4.330

10.  The Systemic Metabolic Profile Early after Allogeneic Stem Cell Transplantation: Effects of Adequate Energy Support Administered through Enteral Feeding Tube.

Authors:  Tor Henrik Anderson Tvedt; Kristin J Skaarud; Geir Erland Tjønnfjord; Tobias Gedde-Dahl; Per Ole Iversen; Øystein Bruserud
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-14       Impact factor: 5.742

View more
  3 in total

Review 1.  Novel approaches for long-term lung transplant survival.

Authors:  Cynthia L Miller; Jane M O; James S Allan; Joren C Madsen
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

Review 2.  The Role of IL-6 in Fibrotic Diseases: Molecular and Cellular Mechanisms.

Authors:  Yanxia Li; Jing Zhao; Yuan Yin; Ke Li; Chenchen Zhang; Yajuan Zheng
Journal:  Int J Biol Sci       Date:  2022-08-29       Impact factor: 10.750

Review 3.  IL-6 Directed Therapy in Transplantation.

Authors:  Cynthia L Miller; Joren C Madsen
Journal:  Curr Transplant Rep       Date:  2021-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.